AIM： To determine the causative agents of spontaneous bacterial peritonitis （SBP） in children with liver disease and ascites in our center. METHODS： During a 2.5 year period, from September 2003 to March 2006, 12 ...AIM： To determine the causative agents of spontaneous bacterial peritonitis （SBP） in children with liver disease and ascites in our center. METHODS： During a 2.5 year period, from September 2003 to March 2006, 12 patients with 13 episodes of SBP were studied. In all cases at the time of admission serum albumin and glucose, urinalysis and urine culture was performed. Analysis [white blood cell （WBC） count with differential, albumin, glucose], gram stain, culture by BACTEC method and antibiogram was done on ascitic fluids. Abdominal paracentesis was repeated after 48 h of antibiotic therapy for bacteriologic assay. The patients were followed for at least three months in a gastroenterology clinic. RESULTS： There were 7 girls （58%） and 5 boys （42%） with a median age of 5.2 years （range, 6 mo to 16 years）. All cases had positive ascitic fluid culture. Gram stain was positive in 5 （38.5%） of them. The isolated organisms were S. pneumoniae in 5 （38.5%）, E. coli in 2 （15.3%）, S. viridans in 2 （15.3%）, and K. pneumoniae, H. influenza, Enterococci, and nontypable Streptococcus each in one （7.7%）. All of them except Enterococci were sensitive to ciprofloxacin and ceftriaxone. All ascitic fluid cultures were negative after 48 h of antibiotic therapy. CONCLUSION： S. pneumoniae is the most common cause of SBP in the pediatric age group and we recommend a third generation cephalosporine （e.g., Ceftriaxlone or Cefotaxime） for empirical therapy in children with SBP.展开更多
AIM： To characterize the bifidobacterial microbiota of the colonic mucosa in patients with colon cancer, inflammatory bowel disease or diverticulitis. METHODS： A sample of the distal colonic mucosa was taken during ...AIM： To characterize the bifidobacterial microbiota of the colonic mucosa in patients with colon cancer, inflammatory bowel disease or diverticulitis. METHODS： A sample of the distal colonic mucosa was taken during surgery from a total of 34 patients, twenty-one with diagnosed colorectal cancer, nine with diverticulitis and four with inflammatory bowel disease, requiring surgery for their condition. Bacterial DNA was extracted from the resected mucosal samples and bifidobacterial mucosa-associated microbiota was qualitatively and quantitatively determined by means of qualitative and quantitative PCR. RESULTS： Bifidobacteria were found in 100% of the samples from patients with diverticulitis or IBD and a 76% of those suffering colon cancer. The species B. Iongum and B. bifidum were the most widely found, followed by B. animalis, B. catenulatum and B. adolescentis. B. breve, B. dentium and B. angulatum were not detected in any sample. A significantly higher occurrence of B. Iongum was observed in patients with diverticulitis than in those with colon cancer or IBD （100%, 62% and 75%, respectively, P 〈 0.05）. Similar results were obtained for B, animalis （56%, 0% and 25%, P 〈 0.05）, while B. adolescentis was only found in the mucosa from patients with colon cancer （5 out of 21, 24%）. At the quantitative level, patients with colon cancer or IBD showed lower counts of total Bifidobacterium （4.94 and 5.91 vs 6.96 log Cells/sample, respectively, P 〈 0.05） and of the species B. longum （4.05 and 4.79 vs 6.76, P 〈 0.05） than those with diverticulitis.CONCLUSION： Aberrancies in mucosa associated microbiota are present in different intestinal diseases. This may indicate a role of the microbiota in the pathogenesis of these diseases.展开更多
Using electron spin resonance (ESR) spin labeling technique, we have studied the conformation of sulfhydryl groups(-SH) binding sites in membrane proteins and membrane fluidity of red blood cells (RBCs) from two group...Using electron spin resonance (ESR) spin labeling technique, we have studied the conformation of sulfhydryl groups(-SH) binding sites in membrane proteins and membrane fluidity of red blood cells (RBCs) from two groups of patients with anemia of chronic renal failure (ACRF). One of the groups is composed of patients who were untreated with recombinant human erythropoietin(r-HuEPO), and the other is composed of patients who were treated with r-HuEPO. The results indicated: 1) the conformation of SH group binding site in RBC membrane proteins from former group was different from those of health people. 2)the fluidity in the region near the surface of RBC membrane from former group was lower than those of healthy people. 3) However, the above biophysical properties of RBC membrane from later group were normal. We concluded that RBC membrane in patients with ACRF was abnormal, and the treatment of r-HuEPO may promote the production of normal RBCs, thus ameliorate the biophysical properties of RBCs from the patients with ACRF.展开更多
Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate...Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.展开更多
文摘AIM： To determine the causative agents of spontaneous bacterial peritonitis （SBP） in children with liver disease and ascites in our center. METHODS： During a 2.5 year period, from September 2003 to March 2006, 12 patients with 13 episodes of SBP were studied. In all cases at the time of admission serum albumin and glucose, urinalysis and urine culture was performed. Analysis [white blood cell （WBC） count with differential, albumin, glucose], gram stain, culture by BACTEC method and antibiogram was done on ascitic fluids. Abdominal paracentesis was repeated after 48 h of antibiotic therapy for bacteriologic assay. The patients were followed for at least three months in a gastroenterology clinic. RESULTS： There were 7 girls （58%） and 5 boys （42%） with a median age of 5.2 years （range, 6 mo to 16 years）. All cases had positive ascitic fluid culture. Gram stain was positive in 5 （38.5%） of them. The isolated organisms were S. pneumoniae in 5 （38.5%）, E. coli in 2 （15.3%）, S. viridans in 2 （15.3%）, and K. pneumoniae, H. influenza, Enterococci, and nontypable Streptococcus each in one （7.7%）. All of them except Enterococci were sensitive to ciprofloxacin and ceftriaxone. All ascitic fluid cultures were negative after 48 h of antibiotic therapy. CONCLUSION： S. pneumoniae is the most common cause of SBP in the pediatric age group and we recommend a third generation cephalosporine （e.g., Ceftriaxlone or Cefotaxime） for empirical therapy in children with SBP.
文摘AIM： To characterize the bifidobacterial microbiota of the colonic mucosa in patients with colon cancer, inflammatory bowel disease or diverticulitis. METHODS： A sample of the distal colonic mucosa was taken during surgery from a total of 34 patients, twenty-one with diagnosed colorectal cancer, nine with diverticulitis and four with inflammatory bowel disease, requiring surgery for their condition. Bacterial DNA was extracted from the resected mucosal samples and bifidobacterial mucosa-associated microbiota was qualitatively and quantitatively determined by means of qualitative and quantitative PCR. RESULTS： Bifidobacteria were found in 100% of the samples from patients with diverticulitis or IBD and a 76% of those suffering colon cancer. The species B. Iongum and B. bifidum were the most widely found, followed by B. animalis, B. catenulatum and B. adolescentis. B. breve, B. dentium and B. angulatum were not detected in any sample. A significantly higher occurrence of B. Iongum was observed in patients with diverticulitis than in those with colon cancer or IBD （100%, 62% and 75%, respectively, P 〈 0.05）. Similar results were obtained for B, animalis （56%, 0% and 25%, P 〈 0.05）, while B. adolescentis was only found in the mucosa from patients with colon cancer （5 out of 21, 24%）. At the quantitative level, patients with colon cancer or IBD showed lower counts of total Bifidobacterium （4.94 and 5.91 vs 6.96 log Cells/sample, respectively, P 〈 0.05） and of the species B. longum （4.05 and 4.79 vs 6.76, P 〈 0.05） than those with diverticulitis.CONCLUSION： Aberrancies in mucosa associated microbiota are present in different intestinal diseases. This may indicate a role of the microbiota in the pathogenesis of these diseases.
文摘Using electron spin resonance (ESR) spin labeling technique, we have studied the conformation of sulfhydryl groups(-SH) binding sites in membrane proteins and membrane fluidity of red blood cells (RBCs) from two groups of patients with anemia of chronic renal failure (ACRF). One of the groups is composed of patients who were untreated with recombinant human erythropoietin(r-HuEPO), and the other is composed of patients who were treated with r-HuEPO. The results indicated: 1) the conformation of SH group binding site in RBC membrane proteins from former group was different from those of health people. 2)the fluidity in the region near the surface of RBC membrane from former group was lower than those of healthy people. 3) However, the above biophysical properties of RBC membrane from later group were normal. We concluded that RBC membrane in patients with ACRF was abnormal, and the treatment of r-HuEPO may promote the production of normal RBCs, thus ameliorate the biophysical properties of RBCs from the patients with ACRF.
文摘Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.
